Perspective Therapeutics Inc CATX

US Biotechnology

$2.52 ▲ +0.80% (+$0.02)

🔥 High Short Interest

Open $2.50

Prev Close $2.50

Day Range $2.45 – $2.53

52W Range $1.96 – $6.16

Market Cap $287.66M

Beta 1.90

EPS (TTM) $-1.33

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NYSE MKT LLC
Currency	USD
IPO Date	2002-05-31
Shares Out.	114,050,000
Website	perspectivetherapeutics.com/ ↗
Phone	18009279800
Employees	166
Revenue	$81,000
Gross Profit	$81,000
Net Income	-$26.8M
Free Cash Flow	-$121.3M
Total Assets	$392.0M
Total Liabilities	$68.2M
Equity	$323.9M

About Perspective Therapeutics Inc

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Perspective Therapeutics Inc is a publicly traded company under the ticker symbol CATX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.